TopStocks.com - Premium Stock Alerts

    Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

    January 12, 2026

    SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today highlighted the significant and persistent unmet medical need in heparin-induced thrombocytopenia (HIT) and underscored the promise of its recently acquired investigational drug candidate, VLX-1005, the first and only potent, highly selective 12-LOX inhibitor in clinical testing as a potential new treatment option.

    Cadrenal Therapeutics acquired VLX-1005 in December 2025, recognizing its potential to transform the treatment landscape for HIT and other immune-mediated thrombotic disorders.

    Emerging data from a recent Phase 2 clinical trial evaluating VLX-1005 in individuals with suspected HIT suggest that VLX-1005 may reduce thrombotic complications, supporting its further development as a novel, mechanism-based therapy. Early trial results suggest that selective 12-LOX inhibition may offer a differentiated approach by addressing the immune thrombotic drivers of disease rather than solely suppressing coagulation.

    HIT is a serious immune-mediated reaction to heparin that paradoxically increases the risk of thrombosis despite a drop in platelet count. It occurs when antibodies activate platelets, triggering widespread clot formation in veins and arteries. Thrombotic complications affect a large proportion of patients and are the primary cause of illness and death in HIT. Recent clinical and translational research continues to reinforce the urgent need for safer, more targeted therapies that address the immune-driven platelet activation underlying this disease.

    Recent findings reported in a 2025 American Society of Hematology (ASH) abstract by Shatzel et al. and in a 2025 publication by Ramadan et al. highlight the high incidence and clinical burden of thrombotic complications in HIT, even with current standard-of-care anticoagulation. These data emphasize the limitations of existing therapies, which primarily inhibit coagulation pathways but do not directly modulate the platelet immune responses central to HIT pathophysiology.

    Growing scientific evidence has identified 12-lipoxygenase (12-LOX) as a key mediator of platelet activation and immune thrombotic responses. Foundational work by McKenzie et al. (2022) significantly advanced the understanding of 12-LOX signaling in platelet-driven immune thrombosis, including in HIT, supporting the enzyme as a compelling therapeutic target.

    Historically, however, drug development efforts targeting 12-LOX have been hindered by a lack of selectivity, raising concerns about off-target effects and safety. This challenge has limited the clinical translation of earlier 12-LOX inhibitors.

    VLX-1005 represents a breakthrough in this area. Supported by preclinical and translational studies (Tourdot et al., 2017; Renna et al., 2023), VLX-1005 is the first and only highly selective 12-LOX inhibitor in clinical development. Its selectivity profile is designed to specifically modulate immune-mediated platelet activation while minimizing off-target inhibition of related lipid signaling pathways.

    Cadrenal is moving forward rapidly to engage with the U.S. Food and Drug Administration (FDA) to discuss the design of a potential pivotal Phase 3 registration study for VLX-1005 in HIT.

    “HIT remains a life-threatening condition with a strikingly high risk of thrombosis despite available therapies,” said Quang X. Pham, CEO of Cadrenal Therapeutics. “By selectively targeting 12-LOX, VLX-1005 has the potential to address a core disease mechanism in HIT. We believe this program represents a meaningful opportunity to improve outcomes for patients who currently have limited options.”

    VLX-1005 has received Orphan Drug Designation (ODD) and Fast Track designation from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation oral therapeutics targeting 12-LOX are also under development for type 1 diabetes and other chronic immune-mediated and inflammatory diseases.

    Lytham Partners 2026 Investor Healthcare Summit

    Cadrenal will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit, which will be held virtually at 4:30 p.m. ET on Thursday, January 15, 2026.

    The webcast can be accessed via the conference home page at https://lythampartners.com/hc2026/ or at https://lythampartners.com/hc2026/cvkd. A replay will also be available through the same links.

    About Cadrenal Therapeutics, Inc.

    Cadrenal Therapeutics, Inc. is developing differentiated products that bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations. It currently has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT, tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

    Safe Harbor

    Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding advancing VLX-1005 for the treatment of HIT; continuing to advance novel therapeutics to treat or prevent thrombosis in high-risk patients; the emerging data from VLX-1005 suggesting meaningful potential to improve patient outcomes while maintaining a favorable safety profile; VLX-1005 being a compelling strategic addition to Cadrenal’s pipeline; the payment to Veralox of milestone payments contingent upon the achievement of certain future clinical and regulatory milestones as well as royalties on global sales of the acquired assets upon future commercialization; the structure and terms of the agreement enabling Cadrenal to allocate capital to advancing the clinical development of VLX-1005; and developing transformative therapeutics to overcome the limitations of current anticoagulation therapy. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to advance the clinical development of VLX-1005 for the treatment of HIT; the ability to continue to advance novel therapeutics to treat or prevent thrombosis in high-risk patients; the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    For more information, please contact:

    Cadrenal Therapeutics:

    Matthew Szot, CFO

    press@cadrenal.com

    Investors:

    Lytham Partners, LLC

    Robert Blum, Managing Partner

    602-889-9700

    CVKD@lythampartners.com

    Enjoyed this breakdown?

    Don't miss our next early stock alert.
    Join our SMS list and get real time picks sent straight to your phone the moment we release them.

    Get Instant SMS Alerts

    Fast, free, zero spam. Opt out anytime.

    By joining, you agree to receive recurring SMS alerts from TopStocks. Message and data rates may apply. Reply STOP to unsubscribe.

    MASTER LEGAL DISCLAIMER

    Last Updated: Apr 30, 2026

    Publisher: Relqo Media LLC (Wyoming, United States)

    Subject Company: Cadrenal Therapeutics, Inc. (CVKD)

    IMPORTANT SUMMARY, PLEASE READ FIRST

    This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Penzance LLC to produce and distribute promotional content regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.

    1. NATURE AND INTENT OF THIS COMMUNICATION

    Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company's operations or investment merit.

    2. COMPENSATION FOR CADRENAL THERAPEUTICS, INC. (CVKD)

    Relqo Media LLC ("Relqo Media") has been engaged by Penzance LLC to provide promotional media and digital investor awareness services with respect to Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). The following details outline the nature, scope, and financial terms of this engagement:

    • Relqo Media received cash compensation of $25,000 for a 5 day campaign covering April 27th , 2026, through May 1st 2026.
    • Relqo Media received cash compensation of $25,000 for a 5 day campaign covering March 9th , 2026, through March 13th 2026.
    • Relqo Media received cash compensation of $25,000 for a 4 day campaign covering March 1st , 2026, through March 5th 2026.
    • Relqo Media received cash compensation of $25,000 for a 5 day campaign covering February 23rd , 2026, through february 28th 2026.
    • Relqo Media received cash compensation of $25,000 for a 5 day campaign covering February 18th , 2026, through february 23rd 2026.
    • Relqo Media received cash compensation of $25,000 for a 6 day campaign covering January 25th , 2026, through January 30th 2026.
    • Relqo Media received cash compensation of $25,000 for a 7 day campaign covering January 12, 2026, through January 19, 2026.
    • Relqo Media received cash compensation of $25,000 for a campaign covering December 10, 2025, through December 17, 2025.
    • Relqo Media received cash compensation of $25,000 for a campaign covering December 2, 2025, through December 10, 2025.
    • Relqo Media continued to receive cash compensation on a week to week basis at a rate of $25,000 per week, paid weekly, from July 26, 2025, through September 9, 2025, resulting in aggregate additional compensation of $150,000.
    • Relqo Media received additional cash compensation at the same weekly rate of $25,000 per week, paid weekly, covering the period from June 26, 2025, through July 26, 2025, resulting in aggregate compensation of $100,000.
    • Relqo Media received cash compensation from Penzance LLC for digital investor awareness and promotional services at a rate of $25,000 per week, paid weekly, beginning January 1, 2025, through July 1, 2025, resulting in aggregate compensation of $650,000 during that period.
    • Total Compensation: As of January 19, 2026, Relqo Media has received cumulative cash compensation of $975,000 from Penzance LLC for services rendered in connection with CVKD.
    • Future Compensation: This engagement continues on an open ended basis at a rate of $25,000 per week, paid weekly, until terminated by either party. Accordingly, Relqo Media will continue to receive compensation at this rate beyond January 19, 2026, unless and until such agreement is terminated or modified in writing.
    • Nature of Services: Relqo Media's services include, but are not limited to, creating, publishing, and distributing digital media, promotional articles, newsletters, websites, investor awareness content, social media campaigns, email/SMS marketing, and other investor-focused communications designed to raise awareness of CVKD among retail and institutional investors.
    • Conflict of Interest Statement: Because Relqo Media has been, and will continue to be, compensated directly by Penzance LLC for its services, this relationship represents a material conflict of interest. Relqo Media's communications regarding CVKD, including but not limited to newsletters, articles, press releases, advertisements, websites, emails, SMS alerts, and social media posts, should be understood as paid advertisements that are inherently biased.
    • Securities Ownership Disclosure: Penzance LLC and/or its affiliates, officers, directors, or associated individuals may own, acquire, or dispose of securities of Cadrenal Therapeutics, Inc. before, during, or after the campaign period. This means that while Relqo Media is being compensated to promote CVKD, the entities paying for such services may simultaneously engage in securities transactions involving CVKD stock, which could result in gains or losses to those parties independent of Relqo Media's activities.
    • Investor Warning: All readers, investors, and market participants should assume that any and all promotional communications disseminated by Relqo Media regarding CVKD are issued for the purpose of increasing investor awareness and may have the effect of increasing trading volume and/or the market price of CVKD's securities. Investors are strongly cautioned to conduct their own independent research, due diligence, and analysis of CVKD, including review of all filings made with the Securities and Exchange Commission (SEC), prior to making any investment decision.

    This relationship creates a material conflict of interest. All content distributed by Relqo Media LLC regarding CVKD should be viewed as promotional, financially motivated, and inherently biased.

    3. INTENDED AUDIENCE

    These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.

    4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS

    Relqo Media LLC does not, and has not, independently verified, investigated, audited, or substantiated any statements, representations, or claims made by the featured company, its officers, directors, employees, affiliates, agents, press releases, marketing materials, or any third-party sources.

    Any and all information regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), including but not limited to business descriptions, operational updates, clinical trial progress, scientific data, partnerships, revenue projections, market opportunity estimates, or strategic plans, should be assumed to be unverified, unaudited, incomplete, potentially inaccurate, and subject to change without notice.

    We make no warranties or representations as to the truthfulness, accuracy, reliability, or completeness of such information, and you should not interpret our publication of these statements as an endorsement or confirmation of their validity.

    You should not rely on any company-provided claims, projections, or forward-looking statements for the purpose of making an investment decision. All such statements may be speculative, overstated, selectively presented, or based on assumptions that may never materialize.

    If you choose to invest, you do so entirely at your own risk, and you should conduct thorough, independent due diligence, including reviewing SEC filings, consulting licensed investment professionals, and obtaining independent verification of any material facts, before making any investment decision.

    5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION

    Historically, promotional campaigns for microcap and small-cap securities, particularly those driven by paid advertising, often cause temporary, artificial, and unsustainable increases in share price and trading volume. These movements are typically fueled by short-term speculative interest, promotional circulation, algorithmic trading activity, and momentum-based retail buying rather than any change in the underlying business, operations, or financial condition of the company.

    You should assume and expect that:

    • CVKD's share price may experience sharp, rapid, and potentially extreme increases during the period of active promotion;
    • Trading volume may spike dramatically due to speculative buying pressure, news catalysts amplified by promotional activity, and social media or online forum chatter;
    • Once buying interest subsides, selling begins, or the promotion ends, which may occur suddenly and without notice, the share price may decline precipitously, potentially returning to pre-promotion levels or lower, often within days or even hours; and
    • These price and volume movements are not reflective of intrinsic value and may have no correlation to the company's actual fundamentals or long-term business prospects.

    Past market behavior shows that such promotional price spikes are frequently followed by steep losses, which can be rapid and irreversible. If you purchase shares during or shortly after a promotional period, you should be prepared for the high probability of losing a substantial portion, or all, of your investment.

    By engaging with our content, you acknowledge and agree that you fully understand the speculative, volatile, and high-risk nature of securities subject to promotional activity, and you will not hold Relqo Media LLC responsible for any losses resulting from such trading patterns.

    6. NO RELIANCE, INVESTOR RESPONSIBILITY

    The burden of research, verification, and risk assessment rests entirely with you, the reader. All content produced and distributed by Relqo Media LLC is promotional in nature and should not be the basis for any investment decision. We are not responsible for your interpretation or use of the information contained herein.

    You are solely responsible for:

    • Reviewing and analyzing all publicly available information, including but not limited to SEC filings, audited financial statements, and official company disclosures;
    • Consulting with a licensed, qualified investment professional, attorney, or tax adviser before making any investment decision;
    • Understanding and accepting the risks inherent in microcap and early-stage public companies, which may include extreme volatility, illiquidity, lack of financial transparency, insider selling, share dilution, regulatory challenges, and business failure.

    We make no warranties or representations as to the accuracy, completeness, timeliness, or reliability of any information presented. Any data, figures, or statements regarding the featured company's business, market opportunity, future performance, or partnerships may be incomplete, outdated, or incorrect. You should assume that certain information is based on third-party sources we have not independently verified.

    By viewing our materials, you agree that:

    • You will not rely solely on our communications in making an investment decision;
    • You accept full responsibility for conducting independent due diligence; and
    • Relqo Media LLC and its affiliates will not be liable for any losses or damages arising from your reliance on our content.

    7. FORWARD-LOOKING STATEMENTS, ASSUMPTIONS, AND ACCURACY NOTICE

    Our materials may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as well as other predictive or aspirational language regarding future events, performance, or results. Words such as "anticipates," "expects," "intends," "plans," "believes," "may," "will," "should," "could," "projects," "estimates," "potential," and similar expressions are intended to identify such statements. These statements are inherently uncertain, based on current expectations, estimates, and assumptions that may prove to be incorrect, incomplete, or no longer applicable at the time you read them.

    Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to: changes in market conditions, regulatory decisions, the outcome of clinical trials, competitive pressures, the availability of financing, and broader economic or geopolitical developments.

    Additionally, some information presented in our content is derived from third-party sources, company press releases, or statements from officers, directors, or affiliates of the featured company. We do not independently verify or guarantee the accuracy, completeness, or timeliness of such information. Any claim, projection, or forward-looking statement should be considered purely speculative and potentially outdated..

    You should not place undue reliance on forward-looking statements or assume that they will prove to be accurate. Relqo Media LLC undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, changes in circumstances, or the emergence of new information, except as required by law.

    8. INFORMATION SOURCING, BIAS, AND ACCURACY

    We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.

    Assume all information presented by Relqo Media is:

    • Subjective,
    • Not independently verified,
    • Created to highlight potential upside and omit downsides,
    • Not suitable as the basis for any investment decision.

    9. OWNERSHIP AND TRADING CONFLICTS

    Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including CVKD. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.

    10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT

    We use a range of outreach and promotional tools, including:

    • Email and newsletter distributions,
    • SMS/MMS text campaigns,
    • Social media posts and influencers,
    • Google and native display ads,
    • Press releases, video marketing, and paid content distribution.

    By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.

    11. ADVERTISING LAW COMPLIANCE

    Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC's interpretations of sponsored investment-related communications.

    We make good-faith efforts to disclose all:

    • Compensation arrangements,
    • Conflicts of interest,
    • Risks,
    • Limitations of our role, and
    • The promotional nature of this content.

    We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.

    12. NON-U.S. USERS

    This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country's laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.

    13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY

    All content is provided "as-is" and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:

    • Investment losses,
    • Inaccuracies,
    • Technical delays,
    • User misunderstandings,
    • Omissions or errors in content.

    Total liability for any claim shall not exceed one hundred dollars ($100).

    14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION

    All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.

    15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS

    Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.

    16. FINAL NOTICE, ACCEPTANCE OF TERMS

    We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.

    If you do not accept all terms of this disclaimer in full, you must:

    • Exit our websites,
    • Unsubscribe from our communications,
    • Discontinue viewing all Relqo Media promotional content.

    17. NO RELIANCE

    By viewing or engaging with this content, you agree that:

    • You will not rely on any statements made by Relqo Media for investment purposes,
    • You waive any claim that our content was a material factor in your investment decision,
    • You have read, understood, and accepted this disclaimer in full.

    © 2024 Relqo Media LLC. All Rights Reserved.

    Legal Contact: 📧 support@topstocks.com

    Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801

    Affiliate Disclosure: Relqo Media LLC owns and operates TopStocks.com and all affiliated digital properties.